Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.
Status:
Recruiting
Trial end date:
2022-12-29
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and
preliminary therapeutic efficacy of multiple doses of CFZ533 anti-CD40 monoclonal antibody in
patients with moderately active lupus nephritis.